Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs of distant metastases will be treated with short-term immunotherapy + novel IO combinations (i.e. anti-IL 8, COX2-inhibitors, anti-LAG3). This treatment will be given during the window period until surgical resection of the tumor. The duration of treatment will be in between approximately 6 and 12 weeks.

Trial Details

NCT ID

NCT03026140

Phase

PHASE2

Sponsor

The Netherlands Cancer Institute

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

Nivolumab
Ipilimumab
Celecoxib 200mg
BMS-986253
BMS-986016

Locations (sample)

Amsterdam, Netherlands|52.37403,4.88969
Amsterdam, Netherlands|52.37403,4.88969
Eindhoven, Netherlands|51.44083,5.47778
Haarlem, Netherlands|52.38084,4.63683
Hilversum, Netherlands|52.22333,5.17639

Key Eligibility Criteria

Signed written informed consent
Patients at least 18 years of age
Non-metastatic adenocarcinoma of the colon (and rectosigmoid considered as nonrectal and not undergoing neoadjuvant treatment)
No signs of distant metastases on CT-scan and physical examination;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →